Sodium Butyrate Ameliorates Type 2 Diabetes-Related Sarcopenia Through IL-33-Independent ILC2s/IL-13/STAT3 Signaling Pathway

References

• Sun H, Saeedi P, Karuranga S, et al. IDF Diabetes Atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022;183:109119. doi:10.1016/j.diabres.2021.109119
   PubMed Web of Science ®Google Scholar
• Leenders M, Verdijk LB, van der Hoeven L, et al. Patients with type 2 diabetes show a greater decline in muscle mass, muscle strength, and functional capacity with aging. J Am Med Dir Assoc. 2013;14(8):585–592. doi:10.1016/j.jamda.2013.02.006
   PubMed Web of Science ®Google Scholar
• Izzo A, Massimino E, Riccardi G, et al. A narrative review on sarcopenia in type 2 diabetes mellitus: prevalence and associated factors. Nutrients. 2021;13(1):183. doi:10.3390/nu13010183
   PubMed Web of Science ®Google Scholar
• Cruz-Jentoft AJ, Sayer AA. Sarcopenia. Lancet. 2019;393(10191):2636–2646. doi:10.1016/S0140-6736(19)31138-9
   PubMed Web of Science ®Google Scholar
• Mesinovic J, Zengin A, De Courten B, et al. Sarcopenia and type 2 diabetes mellitus: a bidirectional relationship. Diabetes Metab Syndr Obes. 2019;12:1057–1072. doi:10.2147/DMSO.S186600
   PubMed Web of Science ®Google Scholar
• Mesinovic J, Scott D. Sarcopenia and diabetes mellitus: evidence for a bi-directional relationship. Eur Geriatr Med. 2019;10(5):677–680. doi:10.1007/s41999-019-00230-z
   Web of Science ®Google Scholar
• Ma XY, Chen FQ. Effects of anti-diabetic drugs on sarcopenia: best treatment options for elderly patients with type 2 diabetes mellitus and sarcopenia. World J Clin Cases. 2021;9(33):10064–10074. doi:10.12998/wjcc.v9.i33.10064
   Web of Science ®Google Scholar
• Xu YH, Gao CL, Guo HL, et al. Sodium butyrate supplementation ameliorates diabetic inflammation in db/db mice. J Endocrinol. 2018;238(3):231–244. doi:10.1530/JOE-18-0137
   PubMed Web of Science ®Google Scholar
• Arora T, Tremaroli V. Therapeutic potential of butyrate for treatment of type 2 diabetes. Front Endocrinol. 2021;12:761834. doi:10.3389/fendo.2021.761834
   PubMed Web of Science ®Google Scholar
• Gao Z, Yin J, Zhang J, et al. Butyrate improves insulin sensitivity and increases energy expenditure in mice. Diabetes. 2009;58(7):1509–1517. doi:10.2337/db08-1637
   PubMed Web of Science ®Google Scholar
• Chriett S, Zerzaihi O, Vidal H, et al. The histone deacetylase inhibitor sodium butyrate improves insulin signalling in palmitate-induced insulin resistance in L6 rat muscle cells through epigenetically-mediated up-regulation of Irs1. Mol Cell Endocrinol. 2017;439:224–232. doi:10.1016/j.mce.2016.09.006
   PubMed Web of Science ®Google Scholar
• Bartemes KR, Kita H. Roles of innate lymphoid cells (ILCs) in allergic diseases: the 10-year anniversary for ILC2s. J Allergy Clin Immunol. 2021;147(5):1531–1547. doi:10.1016/j.jaci.2021.03.015
   PubMed Web of Science ®Google Scholar
• Kabata H, Moro K, Koyasu S. The group 2 innate lymphoid cell (ILC2) regulatory network and its underlying mechanisms. Immunol Rev. 2018;286(1):37–52. doi:10.1111/imr.12706
   PubMed Web of Science ®Google Scholar
• Painter JD, Akbari O. Type 2 innate lymphoid cells: protectors in type 2 diabetes. Front Immunol. 2021;12:727008. doi:10.3389/fimmu.2021.727008
   Web of Science ®Google Scholar
• Kastenschmidt JM, Coulis G, Farahat PK, et al. A stromal progenitor and ILC2 niche promotes muscle eosinophilia and fibrosis-associated gene expression. Cell Rep. 2021;35(2):108997. doi:10.1016/j.celrep.2021.108997
   Web of Science ®Google Scholar
• Knudsen NH, Stanya KJ, Hyde AL, et al. Interleukin-13 drives metabolic conditioning of muscle to endurance exercise. Science. 2020;368(6490):6490. doi:10.1126/science.aat3987
   Web of Science ®Google Scholar
• O’Meara CC, Wamstad JA, Gladstone RA, et al. Transcriptional reversion of cardiac myocyte fate during mammalian cardiac regeneration. Circ Res. 2015;116(5):804–815. doi:10.1161/CIRCRESAHA.116.304269
   Web of Science ®Google Scholar
• Stanya KJ, Jacobi D, Liu S, et al. Direct control of hepatic glucose production by interleukin-13 in mice. J Clin Invest. 2013;123(1):261–271. doi:10.1172/JCI64941
   PubMed Web of Science ®Google Scholar
• Ferreira GS, Veening-Griffioen DH, Boon WPC, et al. Comparison of drug efficacy in two animal models of type 2 diabetes: a systematic review and meta-analysis. Eur J Pharmacol. 2020;879:173153. doi:10.1016/j.ejphar.2020.173153
   Web of Science ®Google Scholar
• Sharma K, McCue P, Dunn SR. Diabetic kidney disease in the db/db mouse. Am J Physiol Renal Physiol. 2003;284(6):F1138–F1144. doi:10.1152/ajprenal.00315.2002
   PubMed Web of Science ®Google Scholar
• Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48(1):16–31. doi:10.1093/ageing/afy169
   PubMed Web of Science ®Google Scholar
• Canani RB, Costanzo MD, Leone L, et al. Potential beneficial effects of butyrate in intestinal and extraintestinal diseases. World J Gastroenterol. 2011;17(12):1519–1528. doi:10.3748/wjg.v17.i12.1519
   PubMed Web of Science ®Google Scholar
• Dang G, Wu W, Zhang H, et al. A new paradigm for a new simple chemical: butyrate & immune regulation. Food Funct. 2021;12(24):12181–12193. doi:10.1039/d1fo02116h
   Web of Science ®Google Scholar
• Xiao Y, Guo Z, Li Z, et al. Role and mechanism of action of butyrate in atherosclerotic diseases: a review. J Appl Microbiol. 2021;131(2):543–552. doi:10.1111/jam.14906
   Web of Science ®Google Scholar
• Lee C, Kim BG, Kim JH, et al. Sodium butyrate inhibits the NF-kappa B signaling pathway and histone deacetylation, and attenuates experimental colitis in an IL-10 independent manner. Int Immunopharmacol. 2017;51:47–56. doi:10.1016/j.intimp.2017.07.023
   PubMed Web of Science ®Google Scholar
• Liu L, Li L, Min J, et al. Butyrate interferes with the differentiation and function of human monocyte-derived dendritic cells. Cell Immunol. 2012;277(1–2):66–73. doi:10.1016/j.cellimm.2012.05.011
   PubMed Web of Science ®Google Scholar
• Wiedmer P, Jung T, Castro JP, et al. Sarcopenia - Molecular mechanisms and open questions. Ageing Res Rev. 2021;65:101200. doi:10.1016/j.arr.2020.101200
   PubMed Web of Science ®Google Scholar
• Gregg EW, Menke A. Diabetes and disability. In: Cowie CC, Casagrande SS, editors. Diabetes in America. 3rd ed. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2018.
   Google Scholar
• Mitchell WK, Williams J, Atherton P, et al. Sarcopenia, dynapenia, and the impact of advancing age on human skeletal muscle size and strength; a quantitative review. Front Physiol. 2012;3:260. doi:10.3389/fphys.2012.00260
   PubMed Web of Science ®Google Scholar
• Oberbach A, Bossenz Y, Lehmann S, et al. Altered fiber distribution and fiber-specific glycolytic and oxidative enzyme activity in skeletal muscle of patients with type 2 diabetes. Diabetes Care. 2006;29(4):895–900. doi:10.2337/diacare.29.04.06.dc05-1854
   PubMed Web of Science ®Google Scholar
• Tang G, Du Y, Guan H, et al. Butyrate ameliorates skeletal muscle atrophy in diabetic nephropathy by enhancing gut barrier function and FFA2-mediated PI3K/Akt/mTOR signals. Br J Pharmacol. 2022;179(1):159–178. doi:10.1111/bph.15693
   PubMed Web of Science ®Google Scholar
• Duan Y, Li F, Tan B, et al. Metabolic control of myofibers: promising therapeutic target for obesity and type 2 diabetes. Obes Rev. 2017;18(6):647–659. doi:10.1111/obr.12530
   Web of Science ®Google Scholar
• Qaisar R, Bhaskaran S, Van Remmen H. Muscle fiber type diversification during exercise and regeneration. Free Radic Biol Med. 2016;98:56–67. doi:10.1016/j.freeradbiomed.2016.03.025
   PubMed Web of Science ®Google Scholar
• Schiaffino S, Reggiani C. Fiber types in mammalian skeletal muscles. Physiol Rev. 2011;91(4):1447–1531. doi:10.1152/physrev.00031.2010
   PubMed Web of Science ®Google Scholar
• Fang ZY, Sharman J, Prins JB, et al. Determinants of exercise capacity in patients with type 2 diabetes. Diabetes Care. 2005;28(7):1643–1648. doi:10.2337/diacare.28.7.1643
   Web of Science ®Google Scholar
• Lloyd CM, Snelgrove RJ. Type 2 immunity: expanding our view. Sci Immunol. 2018;3(25). doi:10.1126/sciimmunol.aat1604
   Web of Science ®Google Scholar
• Heredia JE, Mukundan L, Chen FM, et al. Type 2 innate signals stimulate fibro/adipogenic progenitors to facilitate muscle regeneration. Cell. 2013;153(2):376–388. doi:10.1016/j.cell.2013.02.053
   PubMed Web of Science ®Google Scholar
• Chen WY, Wu YH, Tsai TH, et al. Group 2 innate lymphoid cells contribute to IL-33-mediated alleviation of cardiac fibrosis. Theranostics. 2021;11(6):2594–2611. doi:10.7150/thno.51648
   PubMed Web of Science ®Google Scholar
• Rak GD, Osborne LC, Siracusa MC, et al. IL-33-dependent group 2 innate lymphoid cells promote cutaneous wound healing. J Invest Dermatol. 2016;136(2):487–496. doi:10.1038/JID.2015.406
   Web of Science ®Google Scholar
• Riedel JH, Becker M, Kopp K, et al. IL-33-mediated expansion of type 2 innate lymphoid cells protects from progressive glomerulosclerosis. J Am Soc Nephrol. 2017;28(7):2068–2080. doi:10.1681/ASN.2016080877
   Web of Science ®Google Scholar
• Schuler M, Ali F, Chambon C, et al. PGC1alpha expression is controlled in skeletal muscles by PPARbeta, whose ablation results in fiber-type switching, obesity, and type 2 diabetes. Cell Metab. 2006;4(5):407–414. doi:10.1016/j.cmet.2006.10.003
   PubMed Web of Science ®Google Scholar